NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 59.32

+2.3%

Nov 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: david nordic who wrote (317)	6/10/2010 9:57:29 AM
From: david nordic	1 Recommendation Read Replies (2) of 507

Ovarian Cancer NKTR 102 Phase IIB is being extended with 50 patients. NEKTAR is going to aggressively seek approval within 6 months, based on Phase IIB data. The results are superior to any single cancer agent marketed or in clinical today. The best cancer drug in 25 years per the lead cancer investigator. NKTR 102 - Pegylated Irinotecan with a half life extended from 40 hours to 50+ days. 145mg/m2 Q21 was superior to 145mg/m2 Q14 Dosing less often improves the results. 48% response rate for patients with no treatment options. The toxics side effects are in the single digit range. Off patent Irinotecan vs NKTR 102 with patent protection to 2026. Short term value driver for NEKTAR Amgen Neulasta (3B) deal with Nektar ends in July 2010. Nektar royalties are less than 1% and Nektar is prepared to walk away from the deal renewal if the deal is not sweetened to 6%. Interesting! Robin (CEO) said it not worth Nektar's time and effort.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next